Zalicus completed Phase 1 pharmacokinetic and safety studies and has picked the optimal formulation to move into further clinical development, the company said. The selected formulation demonstrated a six-fold improvement in Z160’s bioavailability compared to the previously studied formulation of Z160.
“The lack of adequate pain control in patients with chronic neuropathic pain represents a significant unmet need and important opportunity for novel agents with improved tolerability, enhanced efficacy, and better long-term safety profiles,” said Mark Corrigan, Zalicus president and CEO.
Related Articles on Pain Management:
Pre-Op Educational Video May Reduce Patient Pain
Ameritex Launches Tool for Chronic Pain Assessment
Kentucky Physicians Express Concern Over New ‘Pill Mill’ Law
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
